Delivery of Survivin siRNA Using Cationic Diphenylalanine Vesicles

Abstract

Small interfering RNA(siRNA) has been proved to be a powerful tool for silencing target gene in cells, raising the possibility that siRNA can be employed as a therapy for treating cancers and other genetic diseases. However, siRNA transfection has the limitation due to the difficulty in the delivery of siRNA to target cells and tissues. To explore an efficient biocompatible siRNA delivery system, cationic diphenylalanine vesicles(CDPVs) were constructed to transfer survivin siRNA to human ovarian cancer cells. The morphology of CDPVs was characterized by scanning electron microscopy(SEM) and the distribution of survivin siRNA was characterized by confocal laser scanning microscopy, which reveal that diphenylalanine and the survivin siRNA were successfully co-delivered. After co-incubation for 48 h, the CDPVs/siRNA exhibited enhanced tumor cell growth inhabitation and apoptosis inducted in human SK-OV-3 ovarian carcinoma cells. Overall, CDPVs is an efficient siRNA delivery system and has a promising prospect for cancer therapy.

Keywords

siRNA delivery / Cationic diphenylalanine nanovesicle / Cancer therapy

References

[1] Whitehead K A, Langer R, Anderson D G. Nature Reviews Drug Discovery, 2009, 8(2): 129.

[2] Resnier P, Montier T, Mathieu V, Benoit J P, Passirani C. Biomaterials, 2013, 34(27): 6429.

[3] David S, Pitard B, Benoît J P, Passirani C. Pharmacological Research, 2010, 62(2): 100.

[4] Chang Y, Yang K, Wei P, Huang S S, Pei Y X, Zhao W, Pei Z C. Angewandte Chemie International Edition, 2014, 53(48): 13342.

[5] Bartlett D W, Davis M E. Nucleic Acids Research, 2005, 34(1): 322.

[6] Gary D J, Puri N, Won Y Y. Journal of Controlled Release, 2007, 121(1/2): 64.

[7] Schaffert D, Troiber C, Salcher E E, Fröhlich T, Martin I, Badgujar N, Dohmen C, Edinger D, Kläger R, Maiwald G, Farkasova K, Seeber S, Jahn-Hofmann K, Hadwiger P, Wagner E. Angewandte Chemie International Edition, 2011, 50(38): 8986.

[8] Kulkarni A, DeFrees K, Hyun S H, Thompson D H. Journal of American Chemical Society, 2012, 134(18): 7596.

[9] Yi Y, Kim H J, Mi P, Zheng M, Takemoto H, Toh K, Kim B S, Hayashi K, Naito M, Matsumoto Y, Miyata K, Kataoka K. Journal of Controlled Release, 2016, 244: 247. Pt B

[10] Slowing I I, Vivero-Escoto J L, Wu C W, Lin V S Y. Advanced Drug Delivery Reviews, 2008, 60(11): 1278.

[11] Geisbert T W, Hensley L E, Kagan E, Yu E Z, Geisbert J B, Daddario-DiCaprio K, Fritz E A, Jahrling P B, McClintock K, Phelps J R, Lee A C H, Judge A, Jeffs L B, MacLachlan I. Journal of Infectious Diseases, 2006, 193(12): 1650.

[12] Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, Takimoto R, Takada K, Miyanishi K, Matsunaga T, Takayama T, Niitsu Y. Nature Biotechnology, 2008, 26(4): 431.

[13] Lv H, Zhang S B, Wang B, Cui S H, Yan J. Journal of Controlled Release, 2006, 114(1): 100.

[14] Ma Z, Li J, He F T, Wilson A, Pitt B, Li S. Biochem. Biophys. Res. Commun., 2005, 330(3): 755.

[15] Akhtar S, Benter I. Adv. Drug Deliv. Rev., 2007, 59(2): 164.

[16] Grayson A C R, Doody A M, Putnam D. Pharmaceutical Research(Dordrecht), 2006, 23(8): 1868.

[17] Thomas M, Lu J J, Ge Q, Zhang C C, Chen J Z, Klibanov A M. Proc. Natl. Acad. Sci. USA, 2005, 02(16): 5679.

[18] Werth S, Urban-Klein B, Dai L, Höbel S, Grzelinski M, Bakowsky U, Czubayko F, Aigner A. Journal of Controlled Release, 2006, 112(2): 257.

[19] Yan X H, He Q, Wang K W, Duan L, Cui Y, Li J B. Angew Chem. Int. Ed. Engl., 2010, 46(14): 2431.

[20] Ambrosini G, Adida C, Altieri D C. Nat. Med., 1997, 3(8): 917.

[21] Li F Z, Ambrosini G, Chu E Y, Plescia J, Tognin S, Marchisio P C, Altieri D C. Nature, 1998, 396(6711): 580.

[22] Shen X, Zheng J Y, Shi H, Zhang Z, Wang W Z. American Journal of the Medical Sciences, 2012, 344(1): 52.

[23] Schimmer A D. Cancer Research, 2004, 64(20): 7183.

[24] Yang D Y, Song X S, Zhang J N, Ye L, Wang S J, Che X Y, Wang J B, Zhang Z W, Wang L, Shi W. Acta Biochim. Biophys. Sin., 2010, 42(2): 137.